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Abstract
The purpose of this study was to investigate the sustained release of nicardipine/polymer solid dispersions prepared by
solvent evaporation method. The release pattern of drug from solid dispersions was evaluated by the dissolution test in both
dissolution medium of phosphate buffer pH 6.8 or gastric acid fluid pH 1.2, and was compared with a commercial long acting
product Perdipine®. The results showed that the formulations with lower ratio of Nicardipine/Eudragit RS (N/RS) (below 1/5) had
sustained release effect in gastric acid fluid (pH 1.2). The release rate of formulation of N/RS = 1/5 was slightly faster than that of
Perdipine® in gastric acid fluid in the early stage. On the contrary, the release rate was lower than that of Perdipine® in phosphate
buffer (pH 6.8). The enteric polymers such as HPMCAS-LF grade (HPMCAS) and hydroxypropyl methylcellulose phthalate, HP-55
grade (HPMCP) were incorporated into the formulation of NC/ERS = 1/5 solid dispersion to improve the drug release in both dissolution medium. It was found that the dissolution efficiencies of drug were increased 2.35-21.08 folds with the addition of 20-40%
of enteric polymer in pH 6.8 media. Among these formulations of N/RS/HPMCP = 1/3.5/1.5 had similar dissolution pattern with
Perdipine® in either medium of phosphate buffer or gastric acid fluid ( f 2 values were above 50), showing that the sustained release
dosage form of nicardipine solid dispersions could be developed by using the combination of Eudragit RS and enteric polymer.
Key words: Nicardipine, Eudragit, Enteric polymer, Dissolution test

Introduction
Nicardipine (N), a dihydropyridine calcium channel
antagonist, causes coronary and peripheral vasodilatation by blocking the influx of extracellular calcium across
cell membranes. It has been reported that the action of
nicardipine was arterioselective and effective for the
treatment of hypertension, angina pectoris and cerebrovascular diseases (1-2). Nicardipine has an extensive
hepatic first-pass metabolism(3-4) following oral administration with systemic bioavailability ranging from 20 to
33%. Because of its short biological half-life (2-4 hr), the
drug has to be given frequently (30 mg three times daily).
Further, nicardipine has some side effects such as nausea,
vomiting, f lushing, headache, dyspepsia, anorexia and
diarrhea, probably due to rapid absorption or gastric irritation (3-5). Therefore, to attain a prolonged therapeutic
effect and a reduced incidence of side effects, sustained
release formulations of nicardipine such as alginate gel
beads, tablets, granules and microspheres of nicardipine
hydrochloride (6-9) have been developed to maintain a suitable plasma level for a long period of time, with minimal
frequency of daily administration. It is known that nicardipine is a weak basic drug (pKa 7.2) which is easily solubilized in acidic solution rather than alkaline solution. It
is difficult to prepare a sustained-release dosage form of
a drug when its solubility is pH-dependent (10). Several
* Author for correspondence. Tel: +886-7-3121101 ext. 2261;
Fax: +886-7-3210683; E-mail: pachwu@kmu.edu.tw

attempts to overcome the problem of pH-dependent solubility of weak basic drugs have been approached (11-18).
They are mostly based on the presence of acidic excipients, such as water-soluble or -insoluble polymers or
organic acids, which either increase the permeability of
the drug delivery system by leaching out at higher pH
values or create an acidic micro-environment inside the
polymer matrices and thus keep the solubility of the drug
at high level.
In this study, the water-insoluble polymers such as
Eudragit RL (RL) and Eudragit RS (RS) were used as
retardants to prepare the sustained release dosage form of
nicardipine/polymer solid dispersion by solvent evaporation method. The enteric polymers such as hydroxypropyl
methylcellulose acetate succinate, LF grade (HPMCAS)
and hydroxypropyl methylcellulose phthalate, HP-55
grade (HPMCP) were incorporated into the drug/polymers
solid dispersions to modify the release rate of drug. The
effects of the sustained release of nicardipine from drug/
Eudragit/enteric polymer solid dispersions were evaluated
by the dissolution test and compared with a commercial
long acting product (Perdipine®).

Materials and methods
I. Materials
The following reagents were used: nicardipine hydro-

335
Journal of Food and Drug Analysis, Vol. 14, No. 4, 2006

chloride, p-hydroxybenzoate-butyl ester (TCI, Japan),
Eudragit RS, Eudragit RL (Rohm Pharm, Germany),
hydroxypropyl methylcellulose acetate succinate, LF
grade (HPMCAS), hydroxypropyl methylcellulose phthalate, HP-55 grade (HPMCP) (Shin Etsu, Japan). Perdipine®
was purchased from Yamanouchi (Japan). All other
chemicals and solvents were of analytical reagent grade.
II. Preparation of Drug/Polymer Solid Dispersion
Solid dispersions with differing weight fractions
of nicardipine/Eudragit/enteric polymers (Table 1) were
prepared by solvent evaporation. The drug and polymers
were dissolved in 40 mL of ethanol, and then the solvent
was evaporated off under reduced pressure at 40°C for 24
hr. The residual solid was pulverized and the 20-40 mesh
fraction was used in this study.
III. Differential Scanning Calorimetry
The endothermic peak heights and peak areas from
thermogram of drug, solid dispersion and polymers were
determined and compared using a Perking-Elmer DSC 7
data handling system. Thermograms were recorded from
120 to 200°C at a heating rate of 10°C/min.
IV. Fourier Transformation-Infrared (FTIR) Spectroscopy
Infrared spectra of drug and drug solid dispersion
were acquied using a Perkin Elmer, Spectrum GX FTIR
spectrometer. The sample and potassium bromide at ratio
of 1/10 (w/w) were previously ground. The potassium
bromide disks were prepared by compressing the powders,
under 50 mPa of force for 15 sec in a hydraulic press.

Sixteen scans were carried at a resolution of 4 cm-1, from
2000 to 370 cm-1.
V. X-ray Diffractometry
The powder X-ray diffraction patterns were determined using Model D5000 Siemems Diffractometer with
a Cu-Kα anode and a graphite monochromator. The voltage and current were set at 40 Kv and 30 mA, respectively.
The samples were analyzed in the 2θ angle range of 0-50°
and the process parameters were set as: scan step size of
0.025° (2θ) and scan step time of 1.25 sec.
VI. Drug Release Test
Dissolution tests were performed in 900 mL of aqueous solution including gastric acid fluid pH 1.2 or phosphate buffer pH 6.8 by the paddle method with a rotation
speed of 50 rpm at 37 ± 0.5°C. At fixed time intervals, the
concentration of dissolved drug was automatically monitored UV absorbance at 240 nm. All dissolution experiments were carried out in sextuple.
VI. Data Analysis
The dissolution efficiency (DE) was defined as from
the area under the dissolution curve at time t by the trapezoidal method.
The different release kinetics might ref lect different release mechanisms. Therefore, three kinetic models
including the zero-order release equation (Eq. 1), Higuchi equation (Eq. 2) and first-order equation (Eq. 3) were
applied to process the in vitro data in order to find the
equation with the best fit(19-20).

Table 1. Compositions of the experimental formulations (ratio)
Formulae

Nicardipine

Eudragit RL

Eudragit RS

HPMCAS

N/RL = 1/1

1

1

N/RL = 1/2

1

2

N/RL = 1/3

1

3

N/RL = 1/5

1

5

N/RS = 1/1

1

1

N/RS = 1/2

1

2

N/RS = 1/3

1

3

N/RS = 1/5

1

5

N/RS = 1/6

1

6

N/RS/HPMCSA = 1/4/1

1

4

1

N/RS/HPMCP = 1/3/2

1

3

2

HPMCP

N/RS/HPMCP = 1/4/1

1

4

1

N/RS/HPMCP = 1/3.75/1.25

1

3.75

1.25

N/RS/HPMCP = 1/3.5/1.5

1

3.5

1.5

N/RS/HPMCP = 1/3/2

1

3

2
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Q = k1 t
(Eq. 1)
Q = k 2 (t) 0.5
(Eq. 2)
ln (Q)= k 3 t
(Eq. 3)
where Q is the release percentage at time t. The k1,
k 2 and k 3 are the rate constants of zero-order, Higuchi and
first order model, respectively.
In addition, the similarity factor f 2 is defined by the
following equation and is used to compare the difference
of dissolution profiles between the commercial product
and experimental formulation(21).
f 2 = 50 × log{[1 + (1 / n)

n

Σ (Rt – Tt)2]-0.5 × 100}
t=1

Where n is the number of sampling times, and Rt and
Tt are the individual percentages dissolved at each time
point, t, for the reference and test dissolution profiles,
respectively. A f 2 values of 50 or greater (50-100) ensures
the sameness or equivalence of the two curves and, thus,
the performance of the two products.

Results and Discussion
I. Drug Release Test
The dissolution time courses of nicardipine from
various ratios of drug/Eudragit solid dispersions into
gastric acid f luid pH 1.2 are shown in Figure 1. It can
be seen that the dissolution rates of drug were increased
as the ratio of drug/polymer increased from 1/5 to 1/1.
Regarding the type of polymer, the release rate of drug
from Eudragit RL solid dispersions (Figure 1A) was greater than that of from Eudragit RS solid dispersions (Figure
1B). The results could be explained by considering the
chemical structure of Eudragit. The Eudragit RL and RS
are synthesized from acrylic and methacrylic esters with
high and low content of quaternary ammonium groups (0.2
and 0.1), respectively, thus making up solid dispersions

with different water permeability(22-24). In comparison of
these dissolution patterns of experimental formulations
to Perdipine ®, the Eudragit RL solid dispersions almost
did not have a sustained effect and the Eudragit RS solid
dispersions had significant retardant effect while the
ratio of drug/polymer was below 1/5. The release rate of
formulation of N/RS = 1/6 was slower than Perdipine® in
the period of 6 hrs. Among these formulation, the dissolution pattern of formulation of N/RS = 1/5 was close to that
of Perdipine® most.
Because nicardipine is a weak basic drug, the solubility is pH-dependent(10). The effect of altering the pH value
of dissolution medium was evaluated. As expected, the
release rate of both Perdipine ® and N/RS = 1/5 in phosphate buffer pH 6.8 were remarkably than that in gastric
acid fluid, pH 1.2, which mimics the in vivo absorption
(Figure 2). By examing the dissolution patterns of N/RS
= 1/5 and Perdipine® in either phosphate buffer or gastric
acid f luid for simulating the in vivo absorption, it was
found that in gastric acid fluid, the dissolution rate of N/
RS = 1/5 was slightly higher than that of Perdipine®. On
the contrary, in phosphate buffer, the release rate of drug
from N/RS = 1/5 was lower than Perdipine ®. The result
might be attributed to the Perdipine® formulation components, which includes macrogol, polyoxyethylene sorbitan
fatty acid ester and the capsule body containing sodium
laurylsulfate as inactive ingredient (25). Macrogol, polyoxyethylene sorbitan fatty acid ester and sodium laurylsulfate are surfactants which can enhance the solubility
of drug in medium, thus increasing the dissolution rate.
In this study, the Eudragit RS was chosen as retardant
because it is water-insoluble and its water permeability
is pH independent. Hence, in order to increase the drug
release rate in pH 6.8 medium and decrease the release
rate in pH 1.2 medium, various amounts of enteric polymers such as HPMCAS and HPMCP which dissolved in
alkaline solution were added into the experimental formulations. The dissolution efficiencies of 300 min (ED300)
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Figure 1. Dissolution profiles of nicardipine from drug/Eudragit solid dispersions and commercial product (Perdipine) in gastric acid fluid
pH 1.2. (A for Eudragit RL; B for Eudragit RS).
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were calculated from the area under the dissolution
curve (26) and the results are listed in Table 2. Addition
of 20-40% of enteric polymers could boost the dissolu-

tion efficiencies and dissolution rate up to 2.35-21.08 folds
and 2.64-14.12 folds, respectively, indicating that these
enteric polymer could significantly improve drug release

Table 2. Dissolution efficiency at 300 min (DE300) and release mechanism of correlation coefficients of nicardipine from Eudragit RS/
enteric polymer solid dispersions in phosphate buffer pH 6.8.
Formulae

Enteric polymer
(%)

IR
(DE300)

Rate

IR
(rate)

Zero-order
(r2)

Higuchi
(r2)

First-order
(r2)

518.00 ± 243.09

1

0.25 ± 0.08

1

0.9805

0.9858

0.8274

1989.11 ± 301.90

3.84

1.10 ± 0.20

4.40

0.9922

0.9782

0.8631

DE300

N/RS = 1/5
N/RS/HPMCSA = 1/4/1

HPMCAS

20

N/RS/HPMCAS = 1/3/2

HPMCAS

40

3351.03 ± 526.73

6.47

1.26 ± 0.14

5.04

0.8246

0.9119

0.6528

N/RS/HPMCP = 1/4/1

HPMCP

20

1215.25 ± 130.75

2.35

0.66 ± 0.08

2.64

0.9538

0.9916

0.8564

N/RS/HPMCP = 1/3.75/1.25

HPMCP

25

2494.31 ± 280.39

4.81

1.37 ± 0.10

5.48

0.9908

0.9933

0.8162

N/RS/HPMCP = 1/3.5/1.5

HPMCP

30

5726.12 ± 682.82

11.05

1.99 ± 0.03

7.96

0.9065

0.9663

0.8058

N/RS/HPMCP = 1/3/2

HPMCP

40

10919.80 ± 971.95

21.08

3.53 ± 0.16

14.12

0.9070

0.9679

0.7245

r: correlation coefficient
IR: increment ratio of dissolution efficiency
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Figure 2. Dissolution profiles of nicardipine experimental formulations (N/RS = 1/5; N/RS/HPMCP = 1/3.5/1.5) and commercial product
(Perdipine®) in gastric acid fluid pH 1.2 and phosphate buffer pH 6.8
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Figure 3. DSC thermograms of nicardipine hydrochloride, Eudragit
RS (RS), HPMCAS and N/RS/HPMCP (1/3.5/1.5) solid dispersions.
(Drug 0.5 mg).
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Figure 4. FTIR spectra (in absorbance) of nicardipine hydrochloride, Eudragit RS (RS), HPMCP and N/RS/HPMCP (1.0/3.5/1.5)
solid dispersions.
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in phosphate buffer. Moreover, the increment ratio of
drug release from solid dispersion was increased with
the increase in additional amounts of enteric polymers.
Furthermore, it can be seen that HPMCP had a better
increment effect than HPMCAS. The results were consistent with previous studies (11-12,15,18) which pointed that
the enteric polymers can dissolve at higher pH value, and
thus act as pore-formers to compensate the reduction of
drug solubility. In comparison of the dissolution curves
of experimental formulations with Perdipine®, the f 2 value
between N/RS/HPMCP = 1/3.5/1.5 and Perdipine ® were
57.19 in gastric acid fluid pH 1.2 and 61.97 in phosphate
buffer, respectively, demonstrating the closeness of the
two curves and, thus, the performance of the two products. In addition, the release mechanisms of nicardipine
from these solid dispersions were evaluated on the basis
of theoretical dissolution equations including zero-order,
Higuchi equation and first order kinetic model(19). As
shown in Table 2, the release pattern of nicardipine from
Eudragit solid dispersions corresponded best with Higuchi
equation and diffusion model, and the enteric polymer did
not change the release mechanism. Similar release kinetic
model was also observed in Perdipine ® (Higuchi model,
r 2 > 0.975).
II. Physical Characterizes
The thermograms of pure compounds and corresponding binary system of drug/mixture polymer (1/5)
are presented in Figure 3 (the other data not shown). The
DSC trace of nicardipine was typical of a crystalline
anhydrous substance, exhibiting a sharp endothermic
peak at 174.4°C, corresponding to the melting point of
the drug. The complete disappearance of the nicardipine
endothermic peak was observed for the various ratios of
drug/Eudragit/enteric polymer solid dispersions, indicating that there were strong interaction among nicardipine, Eudragit and enteric polymers in the solid state
and formation of amorphous solid dispersions. From the
FTIR spectroscopy in Figure 4, it was found that a strong
absorption peak of carbony stretching vibration of nicardipine at 1703 cm-1 and some weak absorption peak were
broader and shifted to lower wavenumber, suggesting the
formation of hydrogen bonds between the carbonyl groups
of nicardipine and hydroxyl groups of HPMCP(5,27). The
X-ray diffractograms of nicardipine, polymer and nicardipine dispersion were shown in Figure 5. It was found
that the crystalline peaks of nicardipine disappeared,
showing the entirely amorphous nature of nicardipine in
the solid dispersions.
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Figure 5. X-ray diffractograms of nicardipine hydrochloride,
Eudragit RS (RS), HPMCP and N/RS/HPMCP (1.0/3.5/1.5) solid
dispersions.
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